Clinical Trial Update: A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase II single-arm study evaluating toripalimab with bevacizumab as first-line therapy for advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Toripalimab Injection (JS001) (toripalimab)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | Status: UNKNOWN